The LVVC platform has specific expertise in retroviral (both gamma- and lentivirus-based) and rAAV vector technology and has a wide portfolio of techniques for target-identification and validation (expression, reporters, knock-down, knock-out, etc.). This unique alliance of research expertise has yielded two particular core strengths of the LVVC:
We have developed next generation MLV (murine leukemia virus) vectors with a more random integration site distribution for safer gene therapy with e.g. a potential application in the generation of CAR T cells.
We have developed strong expertise in the generation of viral vector based animal models and the application of (in vivo) molecular imaging techniques like optogenetics and split reporters.
Click here to know more!